AdvisorShares Psychedelics ETF PSIL 深 滬
已收盤 10-17 16:00:00 美东时间
20.3734
+0.499
+2.51%
華盛通- 最 高20.3772
- 今 開19.60
- 成交量 1.43万股
- 最 低 19.18
- 昨 收 19.874
- 總市值 1528.01万
- 52周最高 20.76
- 市盈率 靜 --
- 換手率 1.91%
- 52周最低 9.548
- 委 比 -81.82%
- 總股本 75.00万
- 歷史最高 106.0654
- 量 比 0.56
- 振 幅 6.02%
- 歷史最低 7.6411
- 每 手 1
- 風險率 2.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pacifica Silver Corp. Strengthens Leadership with Key Appointments
Roberto Resources, Inc. ( ($TSE:PSIL) ) just unveiled an update. Pacifica Silve...
09-04 21:38
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Quantum Biopharma's subsidiary, Huge Biopharma Australia, has cleared a regulatory milestone for its neuroprotective compound, Lucid-MS, in a Phase 1 trial.
08-06 02:25
'Doctor Seeking To Reschedule Psilocybin To Treat Dying Patients Demands DEA Update After Agency Agreed To Initiate Federal Review' - Marijuana Moment
https://www.marijuanamoment.net/doctor-seeking-to-res
06-06 22:50
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more.
05-25 04:11
5 ETFs That Beat Market Turmoil With Gains Last Week
Last week had Wall Street facing volatility, tech earnings disappointments, mixed labor data, and rising inflation fears. Gold hit record highs.
02-11 00:05
Why Is Penny Stock Clearmind Gaining Today?
Clearmind Medicine's stock rose 63.9% after receiving IRB approval for its Phase I/IIa trial of CMND-100, a drug for alcohol use disorder.
2024-12-25 00:32
Psilocybin Drug By Psilera Could Treat Frontotemporal Dementia Without Psychoactive Effects
Psilera's trip-free psilocybin drug PSIL-006 clears key safety milestone, potentially offering a breakthrough treatment for frontotemporal dementia.
2024-09-10 02:09
AdvisorShares Announces 1-For-10 Reverse Split Of ETF, Effective September 10, 2024
AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), has announced a reverse split of the issued and outstanding shares of the AdvisorShares Psychedelics ETF. The split will not change the
2024-08-31 04:16
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision.
2024-06-06 03:26
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
2023-11-13 09:39
